- PH-Contemporary Prescribing of Oral Medications in Eye Disease
- PH-Current Trends in Medical Management
- PH-Eye Care Update - Part 1
- PH-Eye Care Update - Part 2
- PH-Glaucoma Case Series: Know Your Pharm
- PH-Local Anesthesia for Optometric Surgeons
- PH-Opioid Epidemic- Do not be a contributor! - Optometrys Responsibility
- PH-Oral Pharmaceuticals in Primary Care Optometry
- PH-Pharmaceutical Treatment of Anterior Segment Inflammatory Conditions
- PH-Prescribing Considerations During Pregnancy
- PH-Simplifying Systemic Antibiotics
- PH-Therapeutic Innovations The Game Changers
- PH-Therapeutic Strategies in Clinical Eye Care
- PH-Therapeutics for Pediatrics: Just Say Yes
- PH-Top 10 Medications and Their Ocular Side Effects
- PH-Toxic Retina: When Systemic Meds Go Bad
- PH-What's Wrong With My Eyes? Changes Systemic Medications May Cause with the Eye or Vision
Home
/
Affiliate Association Resources
/
CE Catalog
/
PH-Pharmacology
/
PH-Autoimmune Disease and the Eye Series 4: The Weight is Over: New Guidelines Help Optometrists Modify Plaquenil Risk
PH-Autoimmune Disease and the Eye Series 4: The Weight is Over: New Guidelines Help Optometrists Modify Plaquenil Risk
Description:
Plaquenil maculopathy is a rare, but visually debilitating complication of using hydroxychloroquine medication. This course details utilizing special testing including Visual Fields and OCT for diagnosis. The 2011 and 2016 American Academy of Ophthalmology management recommendations including treatment and follow-up will be discussed, including what height, weight, and dosage constitutes high risk. New information about risk modification will help the optometrist manage patients on Plaquenil.
Course Code:
AOA259-PH
Speaker(s):
Anthony DeWilde, O.D.
anthony.dewilde@va.gov
Credits:
1
AOA Expiration Date:
3/4/2025